Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
November 1st, 2008 by 
admin Abstract Our neutral is to set communication efficacy, country and ornament of salutation and repetition in patients with continual high-grade
glioma aerated with bevacizumab and irinotecan. We reviewed retrospectively 51 patients with continual high-grade glioma treated
with this compounding at the speechmaker author Hermelin Brain Tumor Center from 11/15/2005 to 04/01/2008. The 6-month progression-free
activity (PFS) for anaplastic gliomas (AGs) was 78.6 and 63.7% for glioblastoma. The norm PFS was 13.4 months for AG and
7.6 months for those with glioblastoma. The coverall activity evaluate (OS) at 6 months was 85.7% for AG and 78.0% for glioblastoma.
The 12-month OS was 77.9% for AG and 42.6% for glioblastoma. The norm OS instance for AGs was not reached and was 11.5 …
Tags: ATM, Brain, Current, glioma, Survival Rate
Posted in Cancer | 